Earned Royalty. In addition, Alnylam will pay Stanford earned royalties on Net Sales as follows: (A) [**]% of Net Sales for a Licensed Product subject to the following;. (B) Such royalty payments shall be reduced up to [**]% (from [**]% of Net Sales down to [**]% of Net Sales) by the amount of royalty paid to access additional intellectual property necessary in order to sell Licensed Products ("Additional Earned Royalties"). (C) Such royalty payments shall be reduced as follows: (1) [**]% if Additional Earned Royalties are [**]% or less. (2) [**]% if Additional Earned Royalties are greater than [**]% but less than [**]%. (3) [**]% if Additional Earned Royalties are equal to or greater than 3% but less than [**]%. (4) [**]% if Additional Earned Royalties are equal to or greater than [**]% but less than [**]%. (5) [**]% if Additional Earned Royalties are equal to or higher than [**]%. (D) Only one royalty is due on each Licensed Product sold by Alnylam or its sublicensees regardless of whether its manufacture, use, importation or sale are or shall be covered by more than one patent or patent application included in Licensed Patents under this Agreement, and no further royalties will be due for use of such Licensed Product by Alnylam or its sublicensee's customers.
Appears in 3 contracts
Samples: Research Collaboration and License Agreement (Alnylam Pharmaceuticals, Inc.), Research Collaboration and License Agreement (Alnylam Pharmaceuticals, Inc.), Research Collaboration and License Agreement (Alnylam Pharmaceuticals, Inc.)
Earned Royalty. In addition, Alnylam will pay Stanford earned royalties on Net Sales as follows:
(A) [**]% of Net Sales for a Licensed Product subject to the following;.
(B) Such royalty payments shall be reduced up to [**]% (from [**]% of Net Sales down to [**]% of Net Sales) by the amount of royalty paid to access additional intellectual property necessary in order to sell Licensed Products ("Additional Earned Royalties").
(C) Such royalty payments shall be reduced as follows:
(1) [**]% if Additional Earned Royalties are [**]% or less.
(2) [**]% if Additional Earned Royalties are greater than [**]% but less than [**]%.
(3) [**]% if Additional Earned Royalties are equal to or greater than 3[**]% but less than [**]%.
(4) [**]% if Additional Earned Royalties are equal to or greater than [**]% but less than [**]%.
(5) [**]% if Additional Earned Royalties are equal to or higher than [**]%.
(D) Only one royalty is due on each Licensed Product sold by Alnylam or its sublicensees regardless of whether its manufacture, use, importation or sale are or shall be covered by more than one patent or patent application included in Licensed Patents under this Agreement, and no further royalties will be due for use of such Licensed Product by Alnylam or its sublicensee's customers.
Appears in 2 contracts
Samples: License Agreement (Alnylam Pharmaceuticals Inc), License Agreement (Alnylam Pharmaceuticals Inc)
Earned Royalty. In addition, Alnylam will pay Stanford [**] earned royalties on Net Sales as follows:
(A) [**]% of Net Sales for a Licensed Product subject to the following;.
(B) Such royalty payments shall be reduced up to [**]% (from [**]% of Net Sales down to [**]% of Net Sales) by the amount of royalty paid to access additional intellectual property necessary in order to sell Licensed Products ("Additional Earned Royalties").
(C) Such royalty payments shall be reduced as follows:
(1) [**]% if Additional Earned Royalties are [**]% or less.
(2) [**]% if Additional Earned Royalties are greater than [**]% but less than [**]%.
(3) [**]% if Additional Earned Royalties are equal to or greater than 3[**]% but less than [**]%.
(4) [**]% if Additional Earned Royalties are equal to or greater than [**]% but less than [**]%.
(5) [**]% if Additional Earned Royalties are equal to or higher than [**]%.
(D) Only one royalty is due on each Licensed Product sold by Alnylam or its sublicensees regardless of whether its manufacture, use, importation or sale are or shall be covered by more than one patent or patent application included in Licensed Patents under this Agreement, and no further royalties will be due for use of such Licensed Product by Alnylam or its sublicensee's customers.
Appears in 1 contract
Samples: Strategic Collaboration and License Agreement (Alnylam Pharmaceuticals Inc)
Earned Royalty. In addition, Alnylam will pay Stanford earned royalties on Net Sales as follows:
(A) [**]% of Net Sales for a Licensed Product subject to the following;.
(B) Such royalty payments shall be reduced up to [**]% (from [**]% of Net Sales down to [**]% of Net Sales) by the amount of royalty paid to access additional intellectual property necessary in order to sell Licensed Products ("“Additional Earned Royalties"”).
(C) Such royalty payments shall be reduced as follows:
(1) [**]% if Additional Earned Royalties are [**]% or less.
(2) [**]% if Additional Earned Royalties are greater than [**]% but less than [**]%.
(3) [**]% if Additional Earned Royalties are equal to or greater than 3[**]% but less than [**]%.
(4) [**]% if Additional Earned Royalties are equal to or greater than [**]% but less than [**]%.
(5) [**]% if Additional Earned Royalties are equal to or higher than [**]%.
(D) Only one royalty is due on each Licensed Product sold by Alnylam or its sublicensees regardless of whether its manufacture, use, importation or sale are or shall be covered by more than one patent or patent application included in Licensed Patents under this Agreement, and no further royalties will be due for use of such Licensed Product by Alnylam or its sublicensee's ’s customers.
Appears in 1 contract
Samples: Strategic Collaboration and License Agreement (Alnylam Pharmaceuticals, Inc.)
Earned Royalty. In addition, Alnylam will pay Stanford earned royalties on Net Sales as follows:
(A) [***]% of Net Sales for a Licensed Product subject to the following;.
(B) Such royalty payments shall be reduced up to [***]% (from [***]% of Net Sales down to [***]% of Net Sales) by the amount of royalty paid to access additional intellectual property necessary in order to sell Licensed Products ("“Additional Earned Royalties"”).
(C) Such royalty payments shall be reduced as follows:
(1) [***]% if Additional Earned Royalties are [***]% or less.
(2) [***]% if Additional Earned Royalties are greater than [***]% but less than [***]%.
(3) [**]% if Additional Earned Royalties are equal to or greater than 3% but less than [**]%.
(4) [**]% if Additional Earned Royalties are equal to or greater than [***]% but less than [***]%.
(4) [***]% if Additional Earned Royalties are equal to or greater than [***]% but less than [***]%.
(5) [***]% if Additional Earned Royalties are equal to or higher than [***]%.
(D) Only one royalty is due on each Licensed Product sold by Alnylam or its sublicensees regardless of whether its manufacture, use, importation or sale are or shall be covered by more than one patent or patent application included in Licensed Patents under this Agreement, and no further royalties will be due for use of such Licensed Product by Alnylam or its sublicensee's ’s customers.
Appears in 1 contract
Samples: Strategic Collaboration and License Agreement (Isis Pharmaceuticals Inc)
Earned Royalty. In addition, Alnylam will pay Stanford earned royalties on Net Sales as follows:
(A) [**]% of Net Sales for a Licensed Product subject to the following;.
(B) Such royalty payments shall be reduced up to [**]% (from [**]% of Net Sales down to [**]% of Net Sales) by the amount of royalty paid to access additional intellectual property necessary in order to sell Licensed Products ("Additional Earned Royalties").
(C) Such royalty payments shall be reduced as follows:
(1) [**]% if Additional Earned Royalties are [**]% or less.
(2) [**]% if Additional Earned Royalties are greater than [**]% but less than [**]%.
(3) [**]% if Additional Earned Royalties are equal to or greater than 3[**]% but less than [**]%.
(4) [**]% if Additional Earned Royalties are equal to or greater than [**]% but less than [**]%.
(5) [**]% if Additional Earned Royalties are equal to or higher than [**]%.
(D) Only one royalty is due on each Licensed Product sold by Alnylam or its sublicensees regardless of whether its manufacture, use, importation or sale are or shall be covered by more than one patent or patent application included in Licensed Patents under this Agreement, and no further royalties will be due for use of such Licensed Product by Alnylam or its sublicensee's customers.
Appears in 1 contract
Samples: Strategic Collaboration and License Agreement (Alnylam Pharmaceuticals Inc)